UY38384A - Inhibidores de egfr de quinazolina novedosos - Google Patents
Inhibidores de egfr de quinazolina novedososInfo
- Publication number
- UY38384A UY38384A UY0001038384A UY38384A UY38384A UY 38384 A UY38384 A UY 38384A UY 0001038384 A UY0001038384 A UY 0001038384A UY 38384 A UY38384 A UY 38384A UY 38384 A UY38384 A UY 38384A
- Authority
- UY
- Uruguay
- Prior art keywords
- egfr inhibitors
- quinazoline egfr
- new quinazoline
- new
- inhibitors
- Prior art date
Links
- 229940121647 egfr inhibitor Drugs 0.000 title abstract 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
El presente documento describe una clase novedosa de inhibidores de EGFR de quinazolina. También se describen composiciones farmacéuticas de estos y un método para tratar cánceres
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862734655P | 2018-09-21 | 2018-09-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY38384A true UY38384A (es) | 2020-04-30 |
Family
ID=69887926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001038384A UY38384A (es) | 2018-09-21 | 2019-09-23 | Inhibidores de egfr de quinazolina novedosos |
Country Status (10)
Country | Link |
---|---|
US (1) | US20210353627A1 (es) |
EP (1) | EP3852762A4 (es) |
JP (1) | JP2022501344A (es) |
KR (1) | KR20210066841A (es) |
CN (1) | CN113056272A (es) |
AR (1) | AR116483A1 (es) |
CA (1) | CA3112198A1 (es) |
TW (1) | TW202023563A (es) |
UY (1) | UY38384A (es) |
WO (1) | WO2020061470A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3201333A1 (en) | 2020-11-11 | 2022-05-19 | Bayer Aktiengesellschaft | N-[2-({4-[3-(anilino)-4-oxo-4,5,6,7-tetrahydro-1h-pyrrolo[3,2-c]pyridin-2-yl]pyridin-3-yl)oxy)ethyl]prop-2-enamide derivatives and similar compounds as egfr inhibitors for the treatment of cancer |
WO2022105908A1 (zh) * | 2020-11-23 | 2022-05-27 | 上海和誉生物医药科技有限公司 | Egfr抑制剂及其制备方法与在药学上的应用 |
WO2022221227A1 (en) | 2021-04-13 | 2022-10-20 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
WO2023213882A1 (en) | 2022-05-04 | 2023-11-09 | Bayer Aktiengesellschaft | Irreversible mutegfr inhibitors |
WO2024028316A1 (en) | 2022-08-02 | 2024-02-08 | Bayer Aktiengesellschaft | 1h-pyrrolo[3,2-b]pyridine derivatives as irreversible inhibitors of mutant egfr for the treatment of cancer |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
WO2004013091A2 (en) * | 2002-08-01 | 2004-02-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | 4-anilido substituted quinazolines and use thereof as inhibitors of epidermal growth factor receptor kinases |
JP2007509059A (ja) * | 2003-10-16 | 2007-04-12 | カイロン コーポレイション | 癌の処置のためのRafキナーゼのインヒビターとしての、2,6−二置換キナゾリン、キノキサリン、キノリンおよびイソキノリン |
US8426429B2 (en) * | 2004-08-06 | 2013-04-23 | Jansssen Pharmaceutica N.V. | 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) |
TWI377944B (en) * | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
US9308235B2 (en) * | 2012-05-09 | 2016-04-12 | Spectrum Pharmaceuticals, Inc. | Treatment of primary and metastatic carcinoma |
KR20230145496A (ko) * | 2016-11-17 | 2023-10-17 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물 |
AR113451A1 (es) * | 2017-10-18 | 2020-05-06 | Spectrum Pharmaceuticals Inc | Inhibidores de tirosina quinasas de la familia de los egfr mutantes |
CN108299398B (zh) * | 2018-04-27 | 2021-04-02 | 广州富瑞价值医疗健康产业有限公司 | 一种具有抗肿瘤活性含咔唑的喹唑啉衍生物及其制药用途 |
-
2019
- 2019-09-20 WO PCT/US2019/052181 patent/WO2020061470A1/en unknown
- 2019-09-20 KR KR1020217011375A patent/KR20210066841A/ko unknown
- 2019-09-20 US US17/278,397 patent/US20210353627A1/en not_active Abandoned
- 2019-09-20 CA CA3112198A patent/CA3112198A1/en active Pending
- 2019-09-20 JP JP2021514970A patent/JP2022501344A/ja active Pending
- 2019-09-20 EP EP19862092.4A patent/EP3852762A4/en not_active Withdrawn
- 2019-09-20 CN CN201980075906.0A patent/CN113056272A/zh active Pending
- 2019-09-23 AR ARP190102695A patent/AR116483A1/es unknown
- 2019-09-23 TW TW108134267A patent/TW202023563A/zh unknown
- 2019-09-23 UY UY0001038384A patent/UY38384A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2022501344A (ja) | 2022-01-06 |
TW202023563A (zh) | 2020-07-01 |
CN113056272A (zh) | 2021-06-29 |
KR20210066841A (ko) | 2021-06-07 |
CA3112198A1 (en) | 2020-03-26 |
AR116483A1 (es) | 2021-05-12 |
WO2020061470A1 (en) | 2020-03-26 |
EP3852762A1 (en) | 2021-07-28 |
EP3852762A4 (en) | 2022-08-17 |
US20210353627A1 (en) | 2021-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY38384A (es) | Inhibidores de egfr de quinazolina novedosos | |
CO2019013010A2 (es) | Inhibidores de kras g12c y métodos para su uso | |
UY37870A (es) | Inhibidores de kras g12c y métodos para utilizarlos campo de la invención | |
CY1123561T1 (el) | Ενωσεις χρησιμες ως αναστολεις κινασης | |
BR112019002331A2 (pt) | anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos | |
EA202092000A1 (ru) | Ингибиторы димеризации egfr и их использование | |
BR112016029662A2 (pt) | compostos de heteroaril para inibição de quinase | |
BR112021024236A2 (pt) | Proteínas multiespecíficas | |
CL2020003339A1 (es) | Inhibidores de ectonucleotidasa y métodos de uso de los mismos | |
CY1124613T1 (el) | Πυριμιδοπυριμιδινονες χρησιμες ως αναστολεις της wee-1 κινασης | |
CO2020015923A2 (es) | Antagonista de gremlin-1 para la prevención y tratamiento del cáncer | |
CL2018001252A1 (es) | Métodos para tratar esclerosis múltiple usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton | |
PH12017501879A1 (en) | Methods for treating cancer | |
EA201892368A1 (ru) | ИНГИБИТОРЫ ErbB И ИХ ПРИМЕНЕНИЕ | |
EA202091337A1 (ru) | Ингибиторы гистонацетилтрансфераз семейства myst | |
BR112018005331A2 (pt) | inibidores de pcna | |
EA201891478A1 (ru) | Способы и композиции для оценки риска возникновения рака | |
EA201890364A1 (ru) | СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ ИНГИБИРОВАНИЯ ROR-ГАММА-t | |
CL2021001363A1 (es) | Métodos de tratamiento de enfermedades con inhibidores de magl. | |
CL2023000892A1 (es) | Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional). | |
EA201892051A1 (ru) | Фармацевтические композиции для лечения злокачественного новообразования | |
CL2022000967A1 (es) | Composiciones y métodos para el tratamiento de enfermedades hepáticas | |
BR112022001336A8 (pt) | Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo | |
CO2020006542A2 (es) | Profármacos de creatina, composiciones y métodos de uso de estos | |
BR112021008200A2 (pt) | Composições e métodos para distúrbios de alfa-1-antitripsina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20240529 |